Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Eteplirsen (AVI-4658) in Duchenne Muscular Dystrophy
NCT00844597Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jan 2009
- Primary completion
- Jun 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jan 2009; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT00844597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00844597.